Outcomes of vagal nerve stimulation in a pediatric population: A single center experience
| Autor: | Tobias Loddenkemper, Camilla Yu, Kyle Remy, Christine Powell, Joseph R. Madsen, Sriram Ramgopal, Imane Abdelmoumen, Mark H. Libenson, Alexander Rotenberg |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Time Factors Adolescent Efficacy medicine.medical_treatment Clinical Neurology Stimulation Cranial Nerve Single Center Young Adult Epilepsy medicine Humans Young adult Child Adverse effect Medically refractory epilepsy Outcome Pediatric business.industry Medical record Brain Seizure control General Medicine medicine.disease Seizure Treatment Outcome Neurology Brain stimulation Child Preschool Anesthesia Female Neurology (clinical) business Vagus nerve stimulation Follow-Up Studies |
| Zdroj: | Seizure. 23:105-111 |
| ISSN: | 1059-1311 |
| DOI: | 10.1016/j.seizure.2013.10.002 |
| Popis: | Objective To evaluate the efficacy of vagus nerve stimulation (VNS) in pediatric patients with medically refractory epilepsy. Method We reviewed the medical records of 252 consecutive patients who underwent VNS implantation at a single center over a 5-year period. Patients with complete 6- and 12-month follow-up data were included. Analysis was also done across various subgroups including gender, age at implantation, seizure type, abnormal MRI findings pre-implantation, number of medications at baseline, history of SE, and duration of epilepsy. Results Complete follow-up data were available for 69 patients. Median seizure reduction for these patients was 50% (Q1: 0%; Q3: 73%) at 6 months and 40% (Q1: −25%; Q3: 75%) at 12 months. When stratified by baseline seizure frequency, there was a significant reduction from baseline of 61% at 6 months and 69% at 12 months for patients in the high-baseline frequency group. There were no significant reductions at month 6 or 12 months for the lower-baseline frequency group. Adverse events were reported in 40.6% (28 out of 69 patients). Six patients had the VNS removed for reasons including lack of efficacy and side effects and were excluded from the study group. Conclusion VNS provides significant seizure reduction, in particular in pediatric patients with a higher baseline seizure frequency. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect